Renalytix PLC
LSE:RENX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
7.5
50.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Renalytix PLC
Accounts Payable
Renalytix PLC
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Renalytix PLC
LSE:RENX
|
Accounts Payable
$2.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Craneware PLC
LSE:CRW
|
Accounts Payable
$17.2m
|
CAGR 3-Years
111%
|
CAGR 5-Years
59%
|
CAGR 10-Years
12%
|
||
Cambridge Cognition Holdings PLC
LSE:COG
|
Accounts Payable
ÂŁ2.6m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
1%
|
||
Intelligent Ultrasound Group PLC
LSE:IUG
|
Accounts Payable
ÂŁ1.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
||
EMIS Group PLC
LSE:EMIS
|
Accounts Payable
ÂŁ34.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
10%
|
||
Doctor Care Anywhere Group PLC
ASX:DOC
|
Accounts Payable
ÂŁ1.9m
|
CAGR 3-Years
39%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
Renalytix PLC
Glance View
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
See Also
What is Renalytix PLC's Accounts Payable?
Accounts Payable
2.9m
USD
Based on the financial report for Jun 30, 2023, Renalytix PLC's Accounts Payable amounts to 2.9m USD.
What is Renalytix PLC's Accounts Payable growth rate?
Accounts Payable CAGR 3Y
10%
Over the last year, the Accounts Payable growth was 19%. The average annual Accounts Payable growth rates for Renalytix PLC have been 10% over the past three years .